Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07189936 · ClinicalTrials.gov registry record · Phase 2

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

A Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT07189936: Recruiting Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome, sponsored by Vanderbilt University Medical Center.

NCT07189936 is a Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 50 participants, below the 4,186-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07189936, a Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo

Primary Outcome

The effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo on circulating monocyte/ T cell doublets, and inflammatory cytokines and compare it to the placebo

Conditions Studied

SARS CoV 2 Infection Post-Acute COVID-19 Syndrome Long COVID-19 Postural Tachycardia Syndrome (POTS)

Interventions

  • DRUG To Measure levels of circulating monocyte/ T cell doublets at Baseline
  • DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
  • DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
  • DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
  • DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo

Study Locations (1)

Tennessee

  • Cyndya Shibao - Nashville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-12-18
Est. Completion 2029-06-30
Phase Phase 2
Vanderbilt University Medical Center

677 total trials

What NCT07189936 shows while recruiting

NCT07189936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,186-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 5 interventions - of which To Measure levels of circulating monocyte/ T cell doublets at Baseline is the first listed.

NCT07189936 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT07189936 about?

NCT07189936 is a clinical study titled "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS". Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCP...

What is the current status of trial NCT07189936?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-12-18. Estimated completion is 2029-06-30.

What conditions does trial NCT07189936 study?

This clinical trial studies the following conditions: SARS CoV 2 Infection, Post-Acute COVID-19 Syndrome, Long COVID-19, Postural Tachycardia Syndrome (POTS).

What interventions are being tested in trial NCT07189936?

The interventions under investigation include: To Measure levels of circulating monocyte/ T cell doublets at Baseline (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment (DRUG), To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA (DIAGNOSTIC_TEST), To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07189936?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07189936 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for SARS CoV 2 Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07189936's enrollment target sits among peer trials

50 33rd of 35 higher than 3 of 35 other SARS CoV 2 Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07189936

Source: ClinicalTrials.gov NCT07189936, the US trial registry maintained by the National Library of Medicine. NCT07189936 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.